Last updated on June 2019

Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer

Brief description of study

This is a multi-centre, open label, phase 2, randomised controlled trial of patients with advanced triple negative breast cancer (TNBC) who have received no more than one line of chemotherapy (not including neoadjuvant or adjuvant therapy) who will be randomised to be treated with SABR 20Gy in 1 followed by atezolizumab or SABR 24Gy in 3 followed by atezolizumab.

Clinical Study Identifier: NCT03464942

Find a site near you

Start Over

Peter MacCallum Cancer Centre

Melbourne, Australia
  Connect »